SNAI1 and ovarian cancer: Similarly, promotion of EMT by hematopoietic PBX interacting protein [248], NANOG [249,250], TWIST1 [251,252], SNAI1 [253] FOXM1 [254] accompanied acquisition of ovarian cancer cell resistance to conventional therapeutic agents, such as cisplatin, carboplatin or paclitaxel.